Orlistat / FASN Cancer Research Results

OLST, Orlistat: Click to Expand ⟱
Features:

Orlistat (tetrahydrolipstatin; anti-obesity drug; OTC 60 mg, Rx 120 mg). A potent, minimally absorbed gastrointestinal lipase inhibitor that reduces dietary fat absorption (~30% at 120 mg TID).

Primary mechanisms (conceptual rank):
1) Irreversible inhibition of gastric + pancreatic lipases (↓ triglyceride hydrolysis)
2) ↓ Chylomicron formation → ↓ systemic lipid flux
3) Secondary metabolic shifts (weight loss–mediated insulin sensitivity changes)

Bioavailability / PK relevance: Very low systemic absorption (<1%); primary action is intraluminal in gut. Most systemic mechanistic cancer data derive from higher in-vitro concentrations or off-target effects (e.g., FASN inhibition).

In-vitro vs oral exposure: Many anti-cancer studies use concentrations likely exceeding achievable plasma levels from standard dosing (qualifier: high concentration only for direct tumor cytotoxicity).

Clinical evidence status: Approved for obesity; cancer evidence largely preclinical/observational; no robust oncology RCT indication.

Inhibits lipase and is used to facilitate weight loss.

Orlistat — Cancer vs Normal Cell Pathway Map

Rank Pathway / Axis Cancer Cells Normal Cells TSF Primary Effect Notes / Interpretation
1 Fatty Acid Synthase (FASN) ↓ (high concentration only) ↔ (low FASN dependence) R/G Lipid synthesis blockade; apoptosis Well-known off-target in vitro; many tumors overexpress FASN. Clinical relevance limited by low systemic exposure.
2 Lipid availability / metabolic flux ↓ (indirect) ↓ (systemic) G Reduced lipid supply Weight-loss–mediated effect; may indirectly reduce pro-tumor metabolic signaling (insulin/IGF axis).
3 PI3K/AKT/mTOR ↓ (model-dependent) ↔ / ↓ (metabolic improvement) R/G Reduced anabolic signaling Often secondary to lipid stress or metabolic shifts; not primary gut mechanism.
4 Apoptosis (caspase activation) ↑ (high concentration only) ↔ R/G Programmed cell death Observed in cancer lines at supra-physiologic levels; translation uncertain.
5 ROS / lipid peroxidation stress ↑ (lipid stress–related; model-dependent) ↔ P/R Metabolic oxidative stress Linked to FASN inhibition; not central to approved mechanism.
6 NRF2 axis ↔ (insufficient evidence) ↔ R/G Not a dominant axis No consistent evidence of primary NRF2 modulation at therapeutic exposure.
7 Ferroptosis (lipid metabolism link) ↑ (theoretical / model-dependent) ↔ R/G Lipid vulnerability shift FASN inhibition could alter lipid composition; ferroptosis relevance remains investigational.
8 HIF-1α / Warburg coupling ↓ (indirect; metabolic improvement) ↔ G Reduced pro-growth metabolic signaling Likely secondary to weight loss and insulin reduction rather than direct tumor action.
9 Ca²⁺ signaling ↔ ↔ P/R No primary role Not a recognized mechanistic axis for orlistat.
10 Clinical Translation Constraint ↓ (constraint) ↓ (constraint) — Minimal systemic exposure Low absorption limits direct anti-tumor applicability; GI side effects and fat-soluble vitamin malabsorption noted.

TSF legend: P: 0–30 min; R: 30 min–3 hr; G: >3 hr
FASN, Fatty acid synthase: Click to Expand ⟱
Source:
Type:
Fatty acid synthase (FASN) is an enzyme involved in the synthesis of fatty acids, which are essential for cell growth and proliferation. Overexpression of FASN has been observed in various types of cancer, and it is often associated with poor prognosis.
-fatty acid synthase (FAS) has been demonstrated to play an important role in carcinogenesis by protecting cells from apoptosis

FASN (fatty acid synthase) is a key enzyme in the de novo synthesis of fatty acids and has been widely studied in cancer due to its role in lipid metabolism and energy production. Altered FASN expression has been reported in various malignancies, and its prognostic implications have been explored across several tumor types.

FASN is frequently overexpressed in a variety of cancers, including breast, prostate, colorectal, ovarian, and others.
• Many cancers require high levels of fatty acid synthesis for the generation of new membranes and for signaling lipid molecules.
• Higher FASN expression is generally associated with more aggressive cancer phenotypes, increased metastatic potential, and poorer patient outcomes.
• Its role in promoting de novo fatty acid synthesis links it directly to the metabolic demands of rapidly dividing cancer cells, making it both a prognostic biomarker and a promising therapeutic target.
Scientific Papers found: Click to Expand⟱
969- OLST,    Orlistat as a FASN inhibitor and multitargeted agent for cancer therapy
- Review, NA, NA
FASN↓,
1045- OLST,    Fatty acid synthase inhibitor orlistat impairs cell growth and down-regulates PD-L1 expression of a human T-cell leukemia line
- in-vitro, AML, Jurkat
FASN↓, TumCG↓, PD-L1↓,
1226- OLST,    Knockdown of PGM1 enhances anticancer effects of orlistat in gastric cancer under glucose deprivation
- vitro+vivo, GC, NA
PGM1∅, FASN↓, Apoptosis↑, lipidLev↑, GlucoseCon↑, eff↑,
1251- RT,  OLST,    Rutin and orlistat produce antitumor effects via antioxidant and apoptotic actions
- in-vitro, BC, MCF-7 - in-vitro, PC, PANC1 - in-vivo, NA, NA
TumVol↓, *CEA↓, *FASN↓, *ROS↓, *MDA↓, *GSH↑, Apoptosis↑,

Showing Research Papers: 1 to 4 of 4

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 4

Pathway results for Effect on Cancer / Diseased Cells:


Core Metabolism/Glycolysis ⓘ

FASN↓, 3,   GlucoseCon↑, 1,   lipidLev↑, 1,   PGM1∅, 1,  

Cell Death ⓘ

Apoptosis↑, 2,  

Proliferation, Differentiation & Cell State ⓘ

TumCG↓, 1,  

Immune & Inflammatory Signaling ⓘ

PD-L1↓, 1,  

Drug Metabolism & Resistance ⓘ

eff↑, 1,  

Clinical Biomarkers ⓘ

PD-L1↓, 1,  

Functional Outcomes ⓘ

TumVol↓, 1,  
Total Targets: 10

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress ⓘ

GSH↑, 1,   MDA↓, 1,   ROS↓, 1,  

Core Metabolism/Glycolysis ⓘ

FASN↓, 1,  

Migration ⓘ

CEA↓, 1,  

Clinical Biomarkers ⓘ

CEA↓, 1,  
Total Targets: 6

Scientific Paper Hit Count for: FASN, Fatty acid synthase
4 Orlistat
1 Rutin
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:14  Target#:931  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page